The Coming Wave of GLP-1 Competition

The global success of GLP-1s has reshaped the metabolic disease landscape, driving unprecedented demand across diabetes, obesity, and adjacent indications. As key patents for leading products (such as semaglutide and tirzepatide) approach expiration in various countries, a new wave of companies, ranging from traditional generics manufacturers to complex peptide manufacturers and hybrid developers, is preparing to enter the market.

However, this is not a typical loss-of-exclusivity scenario. Regulators are aware of the scale of patient exposure and the clinical sensitivity of these therapies. As a result, companies marketing generic GLP-1s should expect heightened scrutiny across the full product lifecycle, including manufacturing controls, pharmacovigilance (PV) systems, and supply chain integrity.

For companies pursuing entry, success will depend less on speed alone and more on the ability to identify and mitigate risk.

Why Semaglutide and Tirzepatide are Different than Traditional Generics

GLP-1s introduce a distinct risk profile compared to conventional small-molecule generics:

  • High Patient Exposure: These products are prescribed at a large scale, often across diverse populations, increasing the statistical likelihood of safety signals and amplifying regulatory scrutiny.
  • Chronic Use: Unlike short-course therapies, GLP-1 agents are used chronically. This requires robust, sustained pharmacovigilance systems capable of detecting and managing long-term and low-frequency adverse events.
  • Complex Manufacturing and Globalized Supply Chains: Peptide synthesis, formulation, device integration (for injectables), and cold chain logistics introduce layers of complexity. Many entrants rely on globally distributed manufacturing networks, increasing the risk of variability and compliance gaps.

These factors take market entry for off-patent GLP-1s from a developmental challenge to a coordinated operational undertaking.

The Four Risk Areas Every Potential GLP-1 Entrant Should Address

1. Pharmacovigilance at Scale

Companies must design pharmacovigilance systems capable of handling high volumes of adverse event data across multiple geographies. Under-resourced or fragmented PV infrastructures can quickly become compliance liabilities.

2. Inspection Readiness under Heightened Scrutiny

Companies entering the GLP-1 space should expect aggressive inspection activity, particularly around data integrity, supplier oversight, and scale-up controls.

3. API Provenance and Supply Chain Integrity

Given the complexity of peptide APIs and the prevalence of multi-tiered sourcing, regulators will closely examine material traceability and supplier qualification.

4. Rapid Scale-Up Without Losing GMP Control

Demand for GLP-1 products is outpacing supply, creating pressure to scale manufacturing rapidly.

Despite the visibility of the opportunity, several recurring gaps, which can create the potential for risk to be underestimated, are emerging among prospective entrants:

  • Disconnected PV systems across affiliates or partners can delay signal detection and create inconsistencies in regulatory submissions.
  • Assuming a traditional abbreviated pathway can lead to underinvestment in comparability, device integration, or clinical considerations.
  • Rapid expansion without corresponding investment in quality infrastructure often results in inspection findings, remediation costs, and delayed market entry.

How Lachman Supports GLP-1 Market Entrants

Navigating the post-patent GLP-1 landscape requires a cross-functional approach that integrates regulatory strategy, quality systems, pharmacovigilance, and supply chain oversight.

Lachman Consultant Services supports companies at each stage of this journey through:

  • End-to-End Risk Assessment: Identifying vulnerabilities across development, manufacturing, and post-market operations before they become regulatory issues.
  • Tactical Remediation and Long-Term Readiness: Addressing immediate gaps while building sustainable systems that withstand ongoing regulatory scrutiny.

By reframing GLP-1 entry as a risk-management challenge, companies can position themselves not only for approval but for durable success in what will inevitably be a highly competitive and closely monitored market. Reach out to us today at LCS@LachmanConsultants.com for a discussion of how we can help your firm prepare for manufacturing and marketing of these products.